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A farewell to didanosine: harm reduction and cost savings by 
eliminating use of didanosine
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Abstract
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor associated with adverse events and 
public health concerns which have diminished its place in clinical practice, particularly in 
resource-rich settings. While international guidelines do not contain ddI-containing regimens in 
preferred first- or second-line antiretroviral therapy (ART), there is no guidance for management 
of patients currently on ddI. In 2012 at least 20 countries purchased a total of $1–2 million of ddI. 
Drug purchase data in that year show 3.2–10.3 times higher costs for ddI compared to lamivudine 
(3TC). Given issues of multiple toxicities, monitoring, drug interactions, inconvenience, and 
virologic efficacy, as well as cost and formulary concerns, national (including resource-limited 
setting) ART programs should consider complete phase-out of ddI.
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Commentary
Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor (NRTI) first synthesized in 
1964 for development as an anti-cancer agent, and was given an indication by the U.S. Food 
and Drug Administration (FDA) in 1991 for treatment of HIV infection.1 It was the second 
approved antiretroviral (ARV) medication, following zidovudine (AZT) in 1987; since then 
over two dozen other ARVs have been licensed, many with less toxicity and easier dosing 
regimens. While initially ddI was used widely in absence of alternatives, its role in 
antiretroviral therapy (ART) has evolved over the past three decades. Patient-level concerns 
such as adverse events and pill burden, together with public health concerns including 
formulary complexity and costs, have diminished the place of ddI in clinical practice, 
particularly in resource-rich settings.
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From 2002 through 2006, World Health Organization (WHO) guidelines recommended ddI 
to be used in second-line regimens for children and adults.2–5 In 2009, WHO issued rapid 
advice to support lamivudine (3TC)-containing regimens for second line instead of ddI-
containing regimens, regardless of the presence or absence of 3TC in the patient’s first-line 
regimen.6 This was re-affirmed in the 2010 and 2013 guidelines.7–9 The reasoning for 
favoring 3TC over ddI included lack of evidence for any advantage of ddI use, and its 
increased “complexity and cost” compared to 3TC. Potential virologic benefit of 
maintaining 3TC in second-line regimens was also cited, through selection or maintenance 
of the M184V mutation which confers resistance to 3TC and may reduce viral replicative 
capacity, although some uncertainty remains concerning the clinical benefit of this 
property.10–12
While the most recent WHO ART guidelines do not contain ddI-containing regimens in 
first- or second-line ART, there is no guidance for management of patients currently on 
ddI.9 Based on international funding and supply system information, in 2012 at least 20 
countries purchased a total of $1–2 million of ddI.13,14 Because ddI is manufactured with 
several dosing strengths and formulations, this could represent up to 10 formulations that 
need to be maintained on a national formulary, complicating an already intricate field of 
ARVs.14 These challenges could be averted through complete removal of ddI from national 
formularies and substitution with 3TC-containing regimens.
There are well-known concerns regarding ddI use which make it suboptimal for lifelong 
ART. Its use depletes the DNA polymerase which is critical in synthesis of mitochondrial 
DNA; this is one mechanism that leads to various forms of mitochondrial toxicity.15 The 
FDA drug label was updated in 2002 to include Boxed Warnings regarding fatal pancreatitis 
and lactic acidosis; FDA also issued a safety alert in 2010 regarding non-cirrhotic portal 
hypertension.1 Several studies and case series about these and other toxicities have been 
published.16–20 Recommended clinical monitoring for patients on ddI includes routine 
retinal examination (optic neuritis and retinal depigmentation are rare but have been 
described), which is seldom available in resource-limited settings (RLS).21 Use of ddI with 
stavudine or with alcohol consumption increases the risk of toxicity. Concurrent use of ddI 
and tenofovir requires a reduction of ddI dosing due to significant drug–drug interaction, 
and also may impair immunologic recovery.1 To maximize ARV potency, ddI should be 
taken at least 1 h prior to, or 2 h following, food or other medications. This dosing schedule, 
as well as a lack of ddI-containing fixed-dose combinations (FDCs) leading to excess pill 
burden, creates barriers for patient adherence.
Additional concerns include that ddI may not actually be virologically active in most 
second-line patients, due to prevalence of L74V and other known resistance mutations in 
NRTI-experienced patients, some having been only recently discovered.22–25 Evidence that 
continued use of ddI in a failing regimen may select for mutations that are associated with 
cross-resistance to other NRTIs, such as the Q151M complex and T69 insertion, has been 
described and could support discontinuation of the drug in patients currently receiving 
it.26–28 These considerations should be viewed in the context of resource-limited settings 
using a public health approach to ART regimen selection without the benefit of patient-level 
genotyping.
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The 2013 WHO consolidated ART guidelines now recommend the use of 3TC rather than 
ddI for second-line ART regimens. International purchasing data for low- and middle-
income countries show that ddI is considerably more expensive than 3TC. Based on the 
2012 Global Fund Price & Quality Reporting System, the additional per-patient direct drug 
cost of ddI compared to single-drug preparations of 3TC ranges from US$74 to US$223/
child/year and $136 to $253/adult/year, depending on weight-adjusted dosing13 (Figure 1). 
This equates to 3.2–10.3 times higher costs for ddI compared to 3TC. Per-patient prices can 
be significantly reduced through FDCs, especially for generic ARVs. Cost savings of using 
3TC could therefore be even higher.
An argument could be made that there are relatively few patients who currently take ddI-
containing regimens and a program-level phase-out would not be worth the effort. However, 
the disadvantages of continued ddI use, as described above, add weight to the value of a 
phase-out. Other than short-term programmatic effort to implement this change, the 
disadvantages of switching patients on ddI-containing regimens to 3TC-containing regimens 
are negligible. In the case of ddI and its role in second-line ART, switching to 3TC is 
sensible regardless of current viral suppression, ddI resistance mutations, or 3TC resistance 
mutations. While mutations associated with 3TC resistance, such as M184V, are quite 
common in treatment-experienced patients, just as for new second-line patients being 
maintained on 3TC per WHO guidelines, these patients likely can still benefit from its 
continuation.
For these reasons, it appears that all patients on ddI could benefit from a single drug 
substitution to 3TC-containing regimens. National ART programs, with their partners and 
supply chain experts, should consider whether the update of their national guidelines might 
include phase-out of ddI. Patient care would be enhanced, given the issues of multiple 
toxicities, monitoring, drug interactions, inconvenience, and virologic efficacy which have 
been described (Table 1). There would also be discernible program-level benefits. Beyond 
the cost savings, the simplification of the formulary would lead to a more streamlined supply 
chain process. Attention could then be focused on the ARVs, including new drug classes and 
improved FDCs, which bring real value to ART programs and to people living with HIV.
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Annual per-patient costs of didanosine and laminvudine through Global Fund Price & 
Quality Reporting System, by weight-adjusted dosing.
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Table 1
Comparative analysis: didanosine versus lamivudine.
Attributes Didanosine Lamivudine
Use in patients starting new
 regimens
Not recommended by WHO Recommended by WHO
Toxicity profile High Low
Recommended monitoring Complex (pancreatic enzymes; retinal exams) None
Drug interactions Many Few
Complications with ethanol Yes (concurrent use increases risk of
 pancreatitis)
No
Timing of dosage Must be separated from food and other ARVs Able to take concurrent with food and
 other ARVs
Fixed-dose combinations None available Several available
Efficacy in second-line due to
 mutations
Variable; L74V frequent; may select for
 multinucleoside mutations
Variable; M184V usually present; may select
 for decreased viral fitness
Cost High Low
Supply chain Complex; high number of formulations Streamlined
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